Literature DB >> 32032792

Pituitary Apoplexy Case Series: Outcomes After Endoscopic Endonasal Transsphenoidal Surgery at a Single Tertiary Center.

Dhiraj J Pangal1, Kelsi Chesney1, Zoe Memel1, Phillip A Bonney1, Ben A Strickland1, John Carmichael2, Mark Shiroishi3, Chia-Shang Jason Liu3, Gabriel Zada4.   

Abstract

BACKGROUND: The management of pituitary apoplexy, caused by acute hemorrhage and/or infarction of a pituitary adenoma, is debated.
OBJECTIVE: To analyze clinical characteristics of patients undergoing endoscopic endonasal approaches (EEAs) for pituitary apoplexy.
METHODS: A retrospective review of patients at our institution from 2012 to 2018 undergoing EEA for pituitary apoplexy diagnosed clinically and with imaging/pathologic findings. Analysis included demographics, symptoms, neuroendocrine deficits, neuroimaging, complications, symptom resolution, and follow-up details.
RESULTS: Fifty patients (mean age, 53 years) were included. Preoperative symptoms included headache (86%), vision loss (62%), and cranial nerve paresis (40%). Mean tumor diameter was 2.7 cm and extrasellar extension was observed in 96% of tumors. Twenty-eight tumors were hemorrhagic (76%), 24 were necrotic (65%), and 13 (35%) had both features. Magnetic resonance imaging showed gross total resection in 58% of patients. Headache and vision loss improved in 87% and 86% of presenting patients. Cranial nerve paresis resolved in 72% of patients, partially improved in 11%, and remained unchanged in 17%. There were no deaths or carotid artery injuries. Surgical complications included postoperative cerebrospinal fluid leak (n = 4, 8%), epistaxis (n = 2, 4%), postoperative abscess (n = 1, 2%), and transient postoperative vision loss requiring reoperation (n = 1, 4%). Endocrinopathies improved in 21% of patients and panhypopituitarism persisted in 48% and developed in 6% of patients. Mean follow-up time was 26 months; 2 patients experienced recurrence.
CONCLUSIONS: EEA for pituitary apoplexy is effective in rapidly improving headache and visual symptoms. Although neuro-ophthalmic deficits often improve over time, panhypopituitarism persists in most patients after surgical resection.
Copyright © 2020. Published by Elsevier Inc.

Entities:  

Keywords:  Apoplexy; Endoscopic; Outcomes; Pituitary; Transsphenoidal

Mesh:

Year:  2020        PMID: 32032792     DOI: 10.1016/j.wneu.2020.01.204

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  7 in total

Review 1.  Neurological Complications of Endocrine Emergencies.

Authors:  Salvador Cruz-Flores
Journal:  Curr Neurol Neurosci Rep       Date:  2021-03-11       Impact factor: 5.081

2.  Predictive Clinical and Surgical Factors Associated with Recurrent Apoplexy in Pituitary Adenomas.

Authors:  Alan Siu; Sanjeet Rangarajan; Michael Karsy; Christopher J Farrell; Gurston Nyquist; Marc Rosen; James J Evans
Journal:  J Neurol Surg B Skull Base       Date:  2021-09-10

3.  Cerebrospinal Fluid Leak after Transsphenoidal Surgery: A Systematic Review and Meta-analysis.

Authors:  Emma M H Slot; Rengin Sabaoglu; Eduard H J Voormolen; Eelco W Hoving; Tristan P C van Doormaal
Journal:  J Neurol Surg B Skull Base       Date:  2021-08-20

4.  Acute Lymphoblastic Leukemia Presenting as Pituitary Apoplexy: A Case Report and Review of the Literature.

Authors:  Rahul Gupta; Urmimala Bhattacharjee; K S Lekshmon; Shakun Chaudhary; Prashant Sharma; Aditya Jandial; Pinaki Dutta
Journal:  Case Rep Endocrinol       Date:  2021-12-28

5.  Endoscopic Endonasal Transsphenoidal Approach for the Surgical Treatment of Pituitary Apoplexy and Clinical Outcomes.

Authors:  Zhixiang Sun Md; Xintao Cai Md; Yu Li Md; Dongqi Shao Md; Zhiquan Jiang PhD
Journal:  Technol Cancer Res Treat       Date:  2021 Jan-Dec

Review 6.  Revisiting Pituitary Apoplexy.

Authors:  Diane Donegan; Dana Erickson
Journal:  J Endocr Soc       Date:  2022-07-26

7.  Surgery for Pituitary Tumor Apoplexy Is Associated with Rapid Headache and Cranial Nerve Improvement.

Authors:  Kevin A Cross; Rupen Desai; Ananth Vellimana; Yupeng Liu; Keith Rich; Gregory Zipfel; Ralph Dacey; Michael Chicoine; Cristine Klatt-Cromwell; Jonathan McJunkin; Patrik Pipkorn; John S Schneider; Julie Silverstein; Albert H Kim
Journal:  Curr Oncol       Date:  2022-07-12       Impact factor: 3.109

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.